一年一度的全球肿瘤学术界饕餮盛宴——美国临床肿瘤学会（ASCO）年会将于美国当地时间2022年6月3~7日召开。今天我们继续为大家梳理本届年会上胃食管、肝胆胰腺肿瘤领域的重磅临床研究进展。

口头报告

<Oral Abstract Session>

地点：In-Person & Live Stream | Hall B1

时间：2022年6月5日周日 | 21:00 – GMT+8 00:00

一项关于晚期胃癌（AGC）二线治疗的开放、多中心、随机、生物标志物综合试验K-Umbrella胃癌研究的初次报告

 

标题：The first report of K-Umbrella Gastric Cancer Study: An open label, multicenter, randomized, biomarker-integrated trial for second-line treatment of advanced gastric cancer (AGC). 

 

摘要号：4001

汇报人: Sun Young Rha

对比接受围手术期阿替利珠单抗联合FLOT 化疗与单独使用 FLOT 治疗可切除食管胃癌患者的手术和病理结局以及病理缓解情况——德国FLOT-AIO和瑞士 SAKK 胃癌组的一项随机、多中心、IIb 期试验DANTE的中期结果

标题：Surgical and pathological outcome, and pathological regression, in patients receiving perioperative atezolizumab in combination with FLOT chemotherapy versus FLOT alone for resectable esophagogastric adenocarcinoma: Interim results from DANTE, a randomized, multicenter, phase IIb trial of the FLOT-AIO German Gastric Cancer Group and Swiss SAKK.

摘要号：4003

汇报人: Salah-Eddin Al-Batran

替莫唑胺vs替莫唑胺和卡培他滨治疗晚期胰腺神经内分泌肿瘤患者的随机研究ECOG-ACRIN E2211：MGMT作为预测性生物标志物的疗效和评估的最终分析

标题：A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: Final analysis of efficacy and evaluation of MGMT as a predictive biomarker (ECOG-ACRIN E2211).

摘要号：4004

汇报人: Pamela L. Kunz 

NET-02：一项对比脂质体伊立替康 （nal-IRI） 联合5-FU/亚叶酸和多西紫杉醇作为进行性肺外神经内分泌癌患者二线治疗多中心、随机、II 期试验 

 

标题：NET-02: A multicenter, randomized, phase II trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients (pts) with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (PD-EP-NEC). 

摘要号：4005

汇报人: Mairead Geraldine McNamara

 

曲妥珠单抗（T-DXd;DS-8201）治疗HER2表达不可切除或复发性胆道癌（BTC）患者的多中心2期研究（HERB试验）

 

标题：Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2- expressing unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trial). 

摘要号：4006

汇报人: Akihiro Ohba

 

晚期胰腺癌患者的适应性体力活动：前瞻性国家随机 GERCOR 试验的结果 

 

标题：Adapted physical activity in patients (Pts) with advanced pancreatic cancer (APACaP): Results from a prospective national randomized GERCOR trial. 

摘要号：4007

汇报人: Cindy Neuzillet

 

诱导化疗后继予放化疗vs单独化疗治疗不可切除局部晚期胰腺癌的随机III期CONKO-007试验的初步结果

标题：Randomized phase III trial of induction chemotherapy followed by chemoradiotherapy or chemotherapy alone for nonresectable locally advanced pancreatic cancer: First results of the CONKO-007 trial.

摘要号：4008

汇报人: Rainer Fietkau

 

序贯nab-紫杉醇/吉西他滨后进行改良的FOLFOX一线治疗转移性胰腺癌：SEQUENCE试验

标题：Sequential nab-paclitaxel/gemcitabine followed by modified FOLFOX for firstline metastatic pancreatic cancer: The SEQUENCE trial. 

摘要号：4002

汇报人: Alfredo Carrato 

临床科学研讨会

< Clinical Science Symposium >

 

地点：In-Person & Live Stream | Hall D1

 

时间：2022年6月4日周六 | 05:30 – GMT+8 07:00

 

FOENIX-CCA2试验的更新结果：futibatinib在伴FGFR2融合/重排的肝内胆管癌（iCCA）中的疗效和安全性

 

标题：Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/ rearrangements.

 

摘要号：4009

 

汇报人: Lipika Goyal

 

转移性胰腺癌患者的随机三臂 II 期研究发现不同生物特征与化学免疫治疗后的生存率相关

 

标题：Distinct biosignatures associate with survival after chemoimmunotherapy in a randomized, three-arm phase II study in patients with metastatic pancreatic cancer.

 

摘要号：4010 

 

汇报人: Lacey J. Padron

 

Nimotuzumab联合吉西他滨vs吉西他滨治疗K-RAS野生型局部晚期或转移性胰腺癌的前瞻性、随机对照、双盲、多中心和III期临床试验

 

标题：Nimotuzumab combined with gemcitabine versus gemcitabine in K-RAS wild-type locally advanced or metastatic pancreatic cancer: A prospective, randomized-controlled, double-blinded, multicenter, and phase III clinical trial.

 

摘要号：LBA4011

 

汇报人:秦叔逵

 

壁报讨论会

 

< Poster Discussion Session >

 

地点：In-Person & Live Stream | Hall D2

 

时间：2022年6月5日周日 | 02:15 – GMT+8 03:45

 

一项随机 II 期ImmunoTACE 试验：肝细胞癌 （HCC） 患者中低剂量环磷酰胺和经动脉化疗栓塞 （TACE）联合或不联合HepG2脉冲刺激的树突状细胞免疫治疗

 

标题：A randomised phase II clinical trial of low-dose cyclophosphamide and transarterial chemoembolization (TACE) with or without vaccination with dendritic cells (DC) pulsed with HepG2 lysate ex vivo in patients with hepatocellular carcinoma (HCC): The ImmunoTACE trial.

 

摘要号：4012

 

汇报人:Yuk Ting Ma  

 

术后肝动脉输注化疗联合FOLFOX改善肝细胞癌伴微血管浸润患者预后：一项前瞻性多中心3期随机对照临床试验结果

 

标题：Postoperative adjuvant hepatic arterial infusion chemotherapy (HAIC) with FOLFOX to improve outcomes of patients with hepatocellular carcinoma with microvascular invasion: A prospective multicenter, phase 3, randomized, controlled clinical trial.

 

摘要号：4013

 

汇报人:李少华

 

术前放化疗联合卡铂/紫杉醇或5-氟尿嘧啶/奥沙利铂治疗食管癌或交界处癌症的随机2期试验

 

标题：Preoperative chemoradiation (CRT) with carboplatin (CBP)/paclitaxel (PCL) (CP) or with 5-fluorouracil (FU)/oxaliplatin (OX) (Fx) for esophageal or junctional cancer: A randomized phase 2 trial.

 

摘要号：4015

 

汇报人:Antoine Adenis

 

术前放化疗联合卡铂/紫杉醇或5-氟尿嘧啶/奥沙利铂治疗食管癌或交界处癌症的随机2期试验

 

标题：Nimotuzumab plus concurrent chemo-radiotherapy versus chemoradiotherapy in unresectable locally advanced esophageal squamous cell carcinoma (ESCC): Interim analysis from a prospective, randomizedcontrolled, double-blinded, multicenter, and phase III clinical trial (NXCEL1311 Study).

 

摘要号：4016

 

汇报人:Xue Meng

 

CLDN18.2 CART 细胞治疗晚期胃/胃食管交界腺癌患者的安全性、耐受性和初步疗效：Ib/II 期研究CT041结果

 

标题：Safety, tolerability, and preliminary efficacy results in patients with advanced gastric/gastroesophageal junction adenocarcinoma from a phase Ib/II study of CLDN18.2 CART-cell therapy (CT041).

 

摘要号：4017

 

汇报人:Changsong QI

 

小肠腺癌的综合基因组学和转录组学表征

 

标题：Comprehensive genomic and transcriptomic characterization of small bowel adenocarcinoma. 

 

摘要号：4018

 

汇报人:Karan Pandya

 

吉西他滨联和顺铂对比卡培他滨在切除淋巴结阳性肝外胆管癌患者中的应用：一项多中心、开放标签、随机、2 期研究STAMP

 

标题：Adjuvant gemcitabine plus cisplatin (GemCis) versus capecitabine (CAP) in patients (pts) with resected lymph node (LN)-positive extrahepatic cholangiocarcinoma (CCA): A multicenter, open-label, randomized, phase 2 study (STAMP). 

 

摘要号：4019

 

汇报人:Changhoon Yoo

 

铂和依托泊苷vs替莫唑胺联和卡培他滨治疗晚期G3非小细胞胃肠神经内分泌肿瘤患者的随机II期研究：ECOG-ACRIN EA2142

 

标题：Randomized phase II study of platinum and etoposide (EP) versus temozolomide and capecitabine (CAPTEM) in patients (pts) with advanced G3 non-small cell gastroenteropancreatic neuroendocrine neoplasms (GEPNENs): ECOG-ACRIN EA2142.

 

摘要号：4020

 

汇报人:Jennifer Rachel Eads  

 

niraparib联和纳武单抗对比ipilimumab治疗铂敏感型晚期胰腺癌患者的一项随机 Ib/II 期研究

 

标题：A randomized phase Ib/II study of niraparib (nira) plus nivolumab (nivo) or ipilimumab (ipi) in patients (pts) with platinum-sensitive advanced pancreatic cancer (aPDAC).

 

摘要号：4021

 

汇报人:Kim Anna Reiss   

 

改良 FOLFIRINOX +CPI-613对比FOLFIRINOX作为转移性胰腺癌患者一线治疗的多中心3 期随机研究 AVENGER500

 

标题：Phase 3, multicenter, randomized study of CPI-613 with modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) as first-line therapy for patients with metastatic adenocarcinoma of the pancreas (AVENGER500).

 

摘要号：4023

 

汇报人:Philip Agop Philip